Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Autologous bone marrow transplantation in a dog with lymphoma: a clinical study

Full text
Author(s):
Buffo de Capua, Maria Luisa [1] ; Dela Coleta, Flavia Eiras [1] ; Miotto, Mariana Rodrigues [1] ; Calazans, Sabryna Gouveia [1] ; Godoy, Aline Vieira [1] ; Massae Nakage, Ana Paula [2] ; Sales Lisbao, Carolina Bonduki ; Daleck, Carlos Roberto [3] ; Santana, Aureo Evangelista [3]
Total Authors: 9
Affiliation:
[1] Univ Estadual Paulista, UNESP, FCAV, Dept Clin & Cirugia Vet, Programa Posgrad, Jaboticabal, SP - Brazil
[2] Ctr Univ Barao Maua, Ribeirao Preto, SP - Brazil
[3] UNESP, FCAV, Dept Clin & Cirugia Vet, Jaboticabal, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Ciência Rural; v. 39, n. 2, p. 580-584, MAR-APR 2009.
Web of Science Citations: 0
Abstract

The objective of this study is to provide the first report of bone marrow transplantation (BMT) in dogs in Brazil. A Rottweiler with cutaneous lymphoma was submitted to a twelve-week Madison-Wisconsin chemotherapy protocol followed by autologous bone marrow transplantation. For this, 10mL kg(-1) of bone marrow was collected simultaneously from both iliac crests and cryopreserved in a freezer at -80 degrees C. The conditioning step was performed by administering cyclophosphamide by intravenous route at 400mg m(-2). Bone marrow was reinfused after defrosting in a water bath at 37 degrees C. Bone marrow nucleated cell counts before and after freezing, showed a small relative loss of nucleated cells (35.10 and 31.80x10(3) mu L(-1), respectively). Cyclophosphamide induced neutropenia which was reverted by a granulocyte colony-stimulating factor (G-CSF) capable of stimulating hematopoetic reconstitution. On the day 360 after transplant the patient was found to be in complete remission. This study indicates that autologous BMT in a dog with lymphoma submitted to myelosuppressive chemotherapy was potentially safe and effective. (AU)